DK2699593T4 - Beta-2 mikroglobulin-deficiente celler - Google Patents

Beta-2 mikroglobulin-deficiente celler Download PDF

Info

Publication number
DK2699593T4
DK2699593T4 DK12720040.0T DK12720040T DK2699593T4 DK 2699593 T4 DK2699593 T4 DK 2699593T4 DK 12720040 T DK12720040 T DK 12720040T DK 2699593 T4 DK2699593 T4 DK 2699593T4
Authority
DK
Denmark
Prior art keywords
microglobulin
beta
deficient cells
deficient
cells
Prior art date
Application number
DK12720040.0T
Other languages
Danish (da)
English (en)
Other versions
DK2699593T3 (da
Inventor
David W Russell
Roli K Hirata
Original Assignee
Univ Washington Through Its Center For Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46051930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2699593(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Washington Through Its Center For Commercialization filed Critical Univ Washington Through Its Center For Commercialization
Publication of DK2699593T3 publication Critical patent/DK2699593T3/da
Application granted granted Critical
Publication of DK2699593T4 publication Critical patent/DK2699593T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/17043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
DK12720040.0T 2011-04-20 2012-04-18 Beta-2 mikroglobulin-deficiente celler DK2699593T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477474P 2011-04-20 2011-04-20
PCT/US2012/034051 WO2012145384A1 (en) 2011-04-20 2012-04-18 Beta-2 microglobulin-deficient cells

Publications (2)

Publication Number Publication Date
DK2699593T3 DK2699593T3 (da) 2017-11-13
DK2699593T4 true DK2699593T4 (da) 2021-02-08

Family

ID=46051930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12720040.0T DK2699593T4 (da) 2011-04-20 2012-04-18 Beta-2 mikroglobulin-deficiente celler

Country Status (6)

Country Link
US (3) US20140134195A1 (https=)
EP (1) EP2699593B2 (https=)
JP (5) JP2014513948A (https=)
CA (2) CA3205636A1 (https=)
DK (1) DK2699593T4 (https=)
WO (1) WO2012145384A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205636A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
FI2838548T3 (fi) * 2012-04-17 2023-10-02 Univ Washington Through Its Center For Commercialization HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt
CA2896053A1 (en) * 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
AU2014277092B2 (en) * 2013-06-03 2019-04-04 Theravectys Lentiviral vectors containing an MHC class I, MHC class II, or beta-2 microglobulin upstream promoter sequence
WO2015121454A1 (en) 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
JP6681837B2 (ja) 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
GB201412494D0 (en) * 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
EP3215623A4 (en) 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN107921148A (zh) 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
JP2019532640A (ja) * 2016-09-29 2019-11-14 ナントクエスト インコーポレイテッド 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞
EP3630809A1 (en) * 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
US10391156B2 (en) * 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
KR20200075851A (ko) * 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
JP2021507924A (ja) * 2017-12-22 2021-02-25 ディストリビューテッド バイオ， インコーポレイテッド 主要組織適合複合体（ｍｈｃ）組成物およびその使用方法
WO2019160077A1 (ja) 2018-02-16 2019-08-22 国立大学法人京都大学 低抗原性細胞の製造方法
CA3177757A1 (en) * 2018-02-16 2019-08-22 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
KR102304549B1 (ko) * 2018-05-30 2021-09-27 주식회사 강스템바이오텍 Hla 유전자가 제거된 인간 유도만능줄기세포 유래 중간엽줄기세포 및 그의 제조 방법
US12331318B2 (en) 2018-07-13 2025-06-17 Lothar Germeroth Non-immunogenic engineered tissue and methods of producing and using the same
JP7669266B2 (ja) 2018-08-31 2025-04-28 ウィスコンシン アラムニ リサーチ ファンデーション 動脈内皮細胞を播種した血管移植片の生成
AU2019336221B2 (en) 2018-09-07 2025-05-15 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
WO2020067993A1 (en) * 2018-09-26 2020-04-02 National University Of Singapore Engineered human mesenchymal stromal cells with low immunogenicity, methods and kits of generating the same
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
KR102691932B1 (ko) 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
TW202115245A (zh) 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
CA3150235A1 (en) 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
PH12022550542A1 (en) 2019-09-05 2023-03-20 Crispr Therapeutics Ag Universal donor cells
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
KR20220084296A (ko) * 2019-10-22 2022-06-21 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 형질전환 돼지, 이의 제조 방법 및 용도, 그리고 인간 면역계 마우스를 제조하는 방법
KR20210090561A (ko) * 2020-01-10 2021-07-20 주식회사 엘지화학 Mhc 및 종양 항원을 동시 발현하는 항원제시세포를 포함하는 조성물 및 이를 이용한 암 치료
CA3175071A1 (en) 2020-03-11 2021-09-16 Bit Bio Limited Method of generating hepatic cells
US20230348854A1 (en) * 2020-05-08 2023-11-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Chimeric antigen receptors (cars) targeting natural killer cells
EP4149525A4 (en) * 2020-05-15 2024-08-28 Rxcell Inc. HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES
WO2021242935A1 (en) * 2020-05-26 2021-12-02 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
BR112023003036A2 (pt) 2020-08-19 2023-04-25 Astellas Pharma Inc Região fc modificada de ocorrência não natural humana de igg especificamente ligando-se a receptor de fc modificado de ocorrência não natural
EP4200023A4 (en) * 2020-08-23 2024-10-30 Applied StemCell, Inc. Hla-f-modified cells and methods
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022129472A1 (en) 2020-12-18 2022-06-23 Novo Nordisk A/S Safe immuno-stealth cells
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022136215A1 (en) 2020-12-21 2022-06-30 Novo Nordisk A/S Safe immuno-stealth cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2022144855A1 (en) 2020-12-31 2022-07-07 Crispr Therapeutics Ag Universal donor cells
TW202246494A (zh) * 2021-01-26 2022-12-01 美商艾姆比斯藥品公司 基因改造肝細胞群
JPWO2022191216A1 (https=) 2021-03-09 2022-09-15
EP4323395A4 (en) * 2021-04-12 2025-04-02 Memorial Sloan Kettering Cancer Center MANIPULATED HLA MOLECULES FOR T CELL AND NK CELL ACTIVATION AND EXPANSION
CN117242173A (zh) 2021-05-03 2023-12-15 安斯泰来再生医药协会 产生成熟角膜内皮细胞的方法
WO2022235869A1 (en) 2021-05-07 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature hepatocytes
EP4359541A4 (en) * 2021-06-23 2025-04-30 Editas Medicine, Inc. Engineered cells for therapy
WO2023047524A1 (ja) 2021-09-24 2023-03-30 公益財団法人京都大学ｉＰＳ細胞研究財団 改変ヒト人工多能性幹細胞の製造方法
WO2023069480A1 (en) * 2021-10-20 2023-04-27 Vascugen, Inc. Hypoimmune vasculogenic cells
CN119072544A (zh) 2022-04-01 2024-12-03 株式会社标志融合 适合于基因工程、细胞工程和细胞药物的细胞及其制造方法
US20260002124A1 (en) 2022-07-01 2026-01-01 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
TW202417614A (zh) 2022-08-23 2024-05-01 安斯泰來再生醫藥協會 用於治療眼部病症的感光救援細胞（prc）組成物及方法
EP4577223A2 (en) * 2022-08-26 2025-07-02 Beam Therapeutics Inc. Modified allogeneic cells and methods and compositions for the preparation thereof
KR20250090297A (ko) 2022-10-25 2025-06-19 다이이찌 산쿄 가부시키가이샤 억제형 kir 에 대한 아고니스트를 사용한 면역 거절의 회피 방법
EP4619033A1 (en) * 2022-11-17 2025-09-24 The Trustees of Indiana University Novel biomarker and target for treating pulmonary hypertension
EP4649150A1 (en) 2023-01-13 2025-11-19 Laverock Therapeutics Limited Cell context-specific gene regulation using inhibitory rnas
EP4735585A1 (en) 2023-06-30 2026-05-06 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells
WO2025070822A1 (ja) * 2023-09-29 2025-04-03 味の素株式会社 Ｈｌａ遺伝子改変細胞
GB202316281D0 (en) * 2023-10-24 2023-12-06 Replay Holdings Inc Methods and compositions for modulating immune cell activity in cellular therapy
WO2025235955A1 (en) * 2024-05-10 2025-11-13 Bluerock Therapeutics Lp Genetically engineered cells for enhanced immune evasion and methods thereof
WO2026035951A2 (en) 2024-08-07 2026-02-12 Legend Biotech Ireland Limited Cells overexpressing cd43 and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
WO1998042838A1 (en) 1997-03-25 1998-10-01 Morphogenesis, Inc. Universal stem cells
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
EP0995798A1 (en) 1998-10-24 2000-04-26 Novimmune Sa Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20040225112A1 (en) 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
JP2007508018A (ja) * 2003-10-08 2007-04-05 べト−ステム インコーポレイテッド 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
US20080299091A1 (en) 2007-04-06 2008-12-04 International Stem Cell Corporation Patient-specific stem cell lines derived from human parthenogenetic blastocysts
JP5267969B2 (ja) 2007-12-04 2013-08-21 学校法人慶應義塾 癌ワクチン
EP2184297A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
CA3205636A1 (en) 2011-04-20 2012-10-26 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
SG11201500799YA (en) 2012-07-31 2015-03-30 Basil M Hantash Hla g-modified cells and methods

Also Published As

Publication number Publication date
JP2014513948A (ja) 2014-06-19
JP7260182B2 (ja) 2023-04-18
EP2699593A1 (en) 2014-02-26
EP2699593B1 (en) 2017-08-30
JP2020202880A (ja) 2020-12-24
CA2833173C (en) 2023-09-05
US20240207378A1 (en) 2024-06-27
US11813318B2 (en) 2023-11-14
JP2018174946A (ja) 2018-11-15
JP2025010296A (ja) 2025-01-20
DK2699593T3 (da) 2017-11-13
US20190381154A1 (en) 2019-12-19
JP2023073426A (ja) 2023-05-25
WO2012145384A1 (en) 2012-10-26
JP7586528B2 (ja) 2024-11-19
CA3205636A1 (en) 2012-10-26
US20140134195A1 (en) 2014-05-15
EP2699593B2 (en) 2020-11-04
CA2833173A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
DK2699593T3 (da) Beta-2 mikroglobulin-deficiente celler
DK2668680T3 (da) Transparente fotovoltaiske celler
DK2775557T3 (da) Brændselscelle
BR112013019995A2 (pt) bio-óleo estável
EP2688642A4 (en) neurostimulator
CO6960510A2 (es) Celdas fotocatalíticas mejoradas
EP3719852C0 (en) SOLAR CELL
DE102011107365A8 (de) Photovoltaik-Modul
DK2568854T3 (da) Sædeindretning
DE112012001603A5 (de) Photovoltaik-Indach
BR112013015345A2 (pt) nacela
EP2743172A4 (en) TANK SUPPORT STRUCTURE AND FLOATING CONSTRUCTION
DK2685554T3 (da) Siliciumdioxid-solcelle
EP2691987A4 (en) PHOTOVOLTAIC STRUCTURE
EP2544283A4 (en) Fuel cell
EP2757623A4 (en) FUEL CELL
EP2724383A4 (en) SOLAR PANEL
DE112011105455T8 (de) Brennstoffzelle
DE112011101133T8 (de) Brennstoffzelle
EP2768053A4 (en) FUEL CELL
EP2800182A4 (en) FUEL CELL SYSTEM
EP2696415A4 (en) FUEL CELL
DK2570659T3 (da) Vindmølle
DE112011102608T8 (de) Cetanzahl-Bestimmungsvorrrichtung
EP2752886A4 (en) SOLAR CELL MODULE